Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
An active specific immunotherapy trial has been implemented in patients with malignant melanoma utilizing the mouse anti-id MAb MK2-23. The latter bears the internal image of the determinant by the anti-HMW-MAA MAb 763.74. The immunogenicity of anti-id MAb MK2-23 is enhanced by conjugation to a carrier and administration with an adjuvant. Anti-id MAb MK2-23 induced humoral anti-HMW-MAA immunity in about 60% of the immunized patients. The latter was associated with a statistically significant survival prolongation. It is suggested that anti-HMW-MAA immunity may have a beneficial effect on the clinical course of the disease by inhibiting the function of HMW-MAA in the biology of melanoma cells.
Mittelman
A
A
Department of Medicine, New York Medical College, Valhalla 10595, USA.
Wang
X
X
Matsumoto
K
K
Ferrone
S
S
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis* / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D000951:Antigens, Neoplasm; D001483:Base Sequence; D002986:Clinical Trials as Topic; D006801:Humans; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D051379:Mice; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins